Prediction Case File
YouTubeTracking Live

Nike Stock Is FINALLY A Buy!

1 extracted signal · 0 resolved · 1 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
27 Aug 2026, 18:09 UTC
Recorded by Tahlil Plus
27 Aug 2026, 18:44 UTC
Video preview for Nike Stock Is FINALLY A Buy!
Source overview

AI-generated source summary

Nike's Q4 earnings report showed revenue of $10.97 billion, beating analyst expectations of $10.86 billion, with adjusted EPS at 20 cents, also exceeding the expected 13 cents. However, the company's performance is weighed down by a significant sales decline in China, where revenues have fallen 30% year-over-year. The broader Chinese sportswear market has grown, but Nike's market share is eroding due to increased competition from brands like Adidas and a perceived lack of innovation. While the company's overall revenue and EPS beat expectations, partly due to recovery from previous tariff impacts and favorable currency-neutral adjustments, the ongoing struggles in its key China market and a generally flat growth trajectory for its core business are causes for concern. The stock's valuation, trading at a forward P/E of approximately 20-22 times earnings, is considered low compared to its historical multiples and the industry average. The dividend yield is approximately 4.2%, with a free cash flow yield of 5.3%, indicating a relatively safe dividend. However, the declining sales in China and increasing competition pose significant risks to future growth, despite the company's efforts to stabilize and grow revenues in other markets.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Tracking Live
Signals
1
Extracted from this source
Open
1
Still being tracked
Successful
0
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Source processing completed

    Source analysis and structured extraction completed.

  5. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  6. Live evaluation in progress

    1 signal remains active.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.2
Tracked signals
326
Historical success
33.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail